Biotech bearish stocks: Prothena Corporation (NASDAQ:PRTA), Oncomed Pharmaceuticals (NASDAQ:OMED), Enanta Pharmaceuticals (NASDAQ:ENTA), Vanda Pharmaceuticals (NASDAQ:VNDA)

Shares of Prothena Corp PLC (NASDAQ:PRTA) were the recipient of a large increase in short interest in the month of January. As of March 14th, there was short interest totaling 824,645 shares, an increase of 35.0% from the February 28th total of 610,797 shares, reports. Prothena Corporation PLC (NASDAQ:PRTA) stock performance was -13.98% in last session and finished the day at $29.60. Traded volume was 515,674.00million shares in the last session and the average volume of the stock remained 279.18K shares. Prothena Corporation PLC (NASDAQ:PRTA) insider ownership is 44.11%.

Late last year, the biopharma major inked a deal with OncoMed Pharmaceuticals Inc (NASDAQ:OMED) for the joint development and commercialization of up to six anti-cancer stem cell candidates from the latter’s biologics pipeline. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) dropped -13.44 percent to $26.22 Friday on volume of 335,657.00million shares. The intra-day range of the stock was $26.00 to $31.98. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) has a market capitalization of $772.98million.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) CEO Jay Luly sold 15,000 shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) stock on the open market in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $39.17, for a total transaction of $587,550.00. Enanta Pharmaceuticals Inc (NASDAQ:ENTA)’s stock on Apr 04, 2014 reported a decrease of -10.47% to the closing price of $34.47. Its fifty two weeks range is $16.18-$43.73. The total market capitalization recorded $632.99million. The overall volume in the last trading session was 532,012.00million shares. In its share capital, ENTA has 18.36million outstanding shares.

Sage Therapeutics, a Cambridge-based biopharmaceutical company, has appointed Howard H. Pien to its board of directors. Pien has been a chairman of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a CNS development company. On Friday, shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) dropped -10.03% to close the day at $15.07. Company return on investment (ROI) is -46.30% and its monthly performance is recorded as 0.60%. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) quarterly revenue growth is 19.22%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone